Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.5 (EPT/NON-RI)

7 Sep 2010 10:58

RNS Number : 2740S
Nomura Code Securities Limited
07 September 2010
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nomura Code Securities Ltd

(b) Name of offeree in relation to whose relevant securities this form relates:

Silence Therapeutics Ltd

(c) Name of the party to the offer with which exempt principal trader is connected:

Silence Therapeutics Ltd

(d) Date dealing undertaken:

06 Sep 2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

 

NO

 

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

1,907

0.0

(2) Derivatives (other than options):

0

(3) Options and agreements to purchase/sell:

0

 

TOTAL:

0

1,907

0.0

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ord

Purchase

50,000

9.75 p

Ord

Purchase

15,000

10 p

Ord

Purchase

50,000

10.5 p

Ord

Purchase

50,000

11.75 p

Ord

Sale

15,000

10 p

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

07 Sep 2010

Contact name:

Niall Campbell

Telephone number:

020 7776 1226

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOUBVKRRBAKRRR
Date   Source Headline
28th Jun 20192:06 pmRNSAdditional Listing
25th Jun 201912:09 pmRNSResult of AGM
24th Jun 20191:20 pmRNSHolding(s) in Company
21st Jun 20192:36 pmRNSHolding(s) in Company
20th Jun 20191:36 pmRNSHolding(s) in Company
20th Jun 20191:00 pmRNSHolding(s) in Company
19th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20194:37 pmRNSHolding(s) in Company
18th Jun 20191:37 pmRNSHolding(s) in Company
18th Jun 201912:28 pmRNSAdditional Listing
28th May 20197:00 amRNSCollaboration with Genomics England
20th May 20194:46 pmRNSAdditional Listing
14th May 20193:00 pmRNSAdditional Listing
30th Apr 20197:00 amRNSAdditional Listing
26th Apr 20192:35 pmRNSAdditional Listing
25th Apr 20194:55 pmRNSAdditional Listing
25th Apr 20197:00 amRNSSilence Therapeutics Announces Board Changes
18th Apr 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSSilence Therapeutics Publication of Annual Report
16th Apr 201911:00 amRNSSilence Therapeutics Announces Board Change
16th Apr 20197:00 amRNSSilence Therapeutics appoints Head of R&D and CMO
4th Apr 20199:09 amRNSHolding(s) in Company
27th Mar 20197:00 amRNSSilence Therapeutics submits CTA for SLN124
11th Mar 20197:00 amRNS2018 Preliminary Results
7th Mar 20197:00 amRNSSilence to Present at Cowen Healthcare Conference
5th Mar 20197:00 amRNSNotice of Results
4th Mar 20193:35 pmRNSHolding(s) in Company
26th Feb 20195:24 pmRNSHolding(s) in Company
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20197:00 amRNSSLN124 granted Orphan Drug Designation by EMA
9th Jan 20197:00 amRNSDeparture of Chief Financial Officer
19th Dec 20187:00 amRNSSilence Therapeutics advances next RNAi medicine
18th Dec 20184:35 pmRNSPrice Monitoring Extension
10th Dec 20187:00 amRNSSettlement and License Agreement with Alnylam
12th Oct 20186:29 pmRNSErratum: Results of Placing - Withdrawn
12th Oct 20185:12 pmRNSResults of Placing
11th Oct 201810:14 amRNSPTAB Upholds Silence Patent
10th Oct 20187:00 amRNSNew divisional patent and injunction application
5th Oct 20182:16 pmRNSHolding(s) in Company
26th Sep 20187:00 amRNSSilence to Present at Healthcare Conference
21st Sep 20182:19 pmRNSAdditional Listing
11th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
30th Aug 201810:53 amRNSHolding(s) in Company
30th Aug 201810:46 amRNSHolding(s) in Company
24th Aug 20187:00 amRNSNotice of Results
20th Aug 20189:30 amRNSSilence Therapeutics Announces Board Change
7th Aug 20187:00 amRNSLitigation: patisiran EU MA imminent
17th Jul 20183:00 pmRNSDirector/PDMR Shareholding
17th Jul 20181:00 pmRNSAppoints David Horn Solomon as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.